Associated tags: Tao, Therapy, DSM-IV codes, IL13, Attention, Pharmaceutical industry, Hook effect, Johnson & Johnson, Science, Disorder, Proteomics, Antibody, Bristol Myers Squibb, Cancer, Epitope, Portola Pharmaceuticals, Chronic obstructive pulmonary disease, Asthma, IL31, IPF
Locations: FREMONT, CA, US, MOUNT SINAI, DC, WASHINGTON, AUSTRALIA, GERMANY
FREMONT, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the Company since its launch in June 2023 to $165 million. Proceeds from the financing will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform.
Key Points:
- The Series B financing was led by Goldman Sachs Alternatives, with participation from new investors Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, and Logos Capital.
- Concurrent with the financing, Colin Walsh, Ph.D., Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, was appointed to the Company’s Board of Directors.
- Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025.
- The Company is also developing discovery stage programs that expand the ATTOBODY platform footprint to novel, difficult-to-drug targets, and offer additional multi-specific combinations.
Tao,
Internal medicine,
Professor,
Patient,
Pulmonology,
Executive Committee,
Drug,
Therapy,
Chairperson,
Sensation,
Genentech,
NSW,
St George's Hospital,
Harvard University,
MTR,
Pediatrics,
Stanford University,
Teaching hospital,
Critical care,
Outline of health sciences,
KCP,
Neuroinflammation,
UCSF,
Research,
Acquisition,
University,
Management,
MPH,
Drug development,
Atopic dermatitis,
Entrepreneurship,
Critical Care Medicine (journal),
Adolescence,
Contact dermatitis,
Science,
Division,
KRYS,
Pharmaceutical industry FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
Key Points:
- Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
- At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
- Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
- To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.
Retrieved on:
Thursday, February 8, 2024
Tao,
Chronic obstructive pulmonary disease,
Therapeutic index,
IL13,
Epitope,
Atopic dermatitis,
Idiopathic pulmonary fibrosis,
COPD,
Therapy,
IPF,
IL31,
Asthma,
DSM-IV codes FREMONT, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics, a biotech company pioneering spatially optimized biparatopic biologics, announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody. Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.
Key Points:
- Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody.
- Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.
- In just eight months, the Attovia team has successfully closed both tranches of the $60 million Series A financing, built a pipeline of five novel programs, and rapidly advanced our lead programs towards the clinic.
- Attovia expects to nominate a development candidate and advance the candidate to IND enabling studies in the second half of 2024.
Tao,
DSM-IV codes,
Portola Pharmaceuticals,
Cancer,
Attention,
Bristol Myers Squibb,
Antibody,
Proteomics,
Disorder,
Investment,
Science,
Johnson & Johnson,
Therapy,
Hook effect,
Pharmaceutical industry,
Vaccine FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumina Ventures.
Key Points:
- The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumina Ventures.
- Attovia will receive an exclusive world-wide license to the Attobody platform and associated intellectual property and pipeline assets in the therapeutic field in exchange for equity and potential milestones and royalties.
- “By creating Attovia with Frazier and other investors, we can give the Attobody platform the dedicated attention and resources it deserves to fully realize its potential,” said Yuling Luo, Ph.D., founder, chairman and CEO of Alamar and co-founder of Attovia.
- “We are thrilled to join the Attovia investor syndicate and to further advance the increasingly promising nanobody field.”
